Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Volatile sulfur compound-producing bacterial enzymes are a functional group of microbial enzymes, most notably L-methionine gamma-lyase (MGL) and cysteine desulfhydrase, that catalyze the degradation of sulfur-containing amino acids into malodorous gases. These enzymes are primarily expressed by anaerobic Gram-negative bacteria such as Porphyromonas gingivalis, Treponema denticola, and Fusobacterium nucleatum, which are common inhabitants of the oral cavity and the gastrointestinal tract. The primary metabolic products—hydrogen sulfide, methyl mercaptan, and dimethyl sulfide—are the main contributors to halitosis and have been implicated in the progression of periodontal disease by inducing inflammation and increasing tissue permeability. Therapeutic interventions often target these enzymes using metal ions like zinc, which both inhibit enzymatic activity and chemically neutralize the produced gases. Additionally, antimicrobial agents and probiotics are used to manage the bacterial populations responsible for enzyme production, while experimental inhibitors like propargylglycine are being explored for more precise enzymatic targeting.
Competitive inhibition of enzyme activity, direct enzymatic blockade, chemical neutralization of metabolic byproducts (VSCs), and reduction of bacterial populations expressing the enzymes.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-methionine gamma-lyase (MGL).